{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:45:11Z","timestamp":1791297911189,"version":"4.1.0"},"reference-count":254,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T00:00:00Z","timestamp":1446422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma (HCC) which are leading indications of liver transplantation (LT). To date, there is no vaccine to prevent HCV infection and LT is invariably followed by infection of the liver graft. Within the past years, direct-acting antivirals (DAAs) have had a major impact on the management of chronic hepatitis C, which has become a curable disease in the majority of DAA-treated patients. In contrast to DAAs that target viral proteins, host-targeting agents (HTAs) interfere with cellular factors involved in the viral life cycle. By acting through a complementary mechanism of action and by exhibiting a generally higher barrier to resistance, HTAs offer a prospective option to prevent and treat viral resistance. Indeed, given their complementary mechanism of action, HTAs and DAAs can act in a synergistic manner to reduce viral loads. This review summarizes the different classes of HTAs against HCV infection that are in preclinical or clinical development and highlights their potential to prevent HCV infection, e.g., following LT, and to tailor combination treatments to cure chronic HCV infection.<\/jats:p>","DOI":"10.3390\/v7112898","type":"journal-article","created":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T10:45:06Z","timestamp":1446461106000},"page":"5659-5685","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection"],"prefix":"10.3390","volume":"7","author":[{"given":"Mirjam","family":"Zeisel","sequence":"first","affiliation":[{"name":"Inserm, U1110, Institut de Recherche sur les Maladies Virales et H\u00e9patiques, 67000 Strasbourg, France"},{"name":"Universit\u00e9 de Strasbourg, 67000 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Crouchet","sequence":"additional","affiliation":[{"name":"Inserm, U1110, Institut de Recherche sur les Maladies Virales et H\u00e9patiques, 67000 Strasbourg, France"},{"name":"Universit\u00e9 de Strasbourg, 67000 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Baumert","sequence":"additional","affiliation":[{"name":"Inserm, U1110, Institut de Recherche sur les Maladies Virales et H\u00e9patiques, 67000 Strasbourg, France"},{"name":"Universit\u00e9 de Strasbourg, 67000 Strasbourg, France"},{"name":"Institut Hospitalo-Universitaire, P\u00f4le H\u00e9pato-digestif, H\u00f4pitaux Universitaires de Strasbourg, 67000 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Schuster","sequence":"additional","affiliation":[{"name":"Inserm, U1110, Institut de Recherche sur les Maladies Virales et H\u00e9patiques, 67000 Strasbourg, France"},{"name":"Universit\u00e9 de Strasbourg, 67000 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,11,2]]},"reference":[{"key":"ref_1","unstructured":"Knipe, D.M., and Howley, P.M. (2007). Fields Virology, Lippincott-Raven."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMp1400986","article-title":"Curing chronic hepatitis C\u2014The arc of a medical triumph","volume":"370","author":"Chung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_3","first-page":"17","article-title":"Cell culture systems for hepatitis C virus","volume":"369","author":"Steinmann","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_4","first-page":"49","article-title":"Animal models for hepatitis C","volume":"369","author":"Billerbeck","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fmicb.2013.00212","article-title":"Hepatitis C virus infection and related liver disease: The quest for the best animal model","volume":"4","author":"Mailly","year":"2013","journal-title":"Front. Microbiol."},{"key":"ref_6","first-page":"87","article-title":"Hepatitis C virus entry","volume":"369","author":"Zeisel","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_7","first-page":"143","article-title":"Hepatitis C virus RNA translation","volume":"369","author":"Niepmann","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_8","first-page":"167","article-title":"Hepatitis C virus RNA replication","volume":"369","author":"Lohmann","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_9","first-page":"199","article-title":"Virion assembly and release","volume":"369","author":"Lindenbach","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.antiviral.2013.09.020","article-title":"Host-targeting agents in the treatment of hepatitis C: A beginning and an end?","volume":"100","author":"Baugh","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1073\/pnas.0912966107","article-title":"Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection","volume":"107","author":"Gastaminza","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1073\/pnas.0915117107","article-title":"A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle","volume":"107","author":"Chockalingam","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"He, S., Lin, B., Chu, V., Hu, Z., Hu, X., Xiao, J., Wang, A.Q., Schweitzer, C.J., Li, Q., and Imamura, M. (2015). Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci. Transl. Med., 7.","DOI":"10.1126\/scitranslmed.3010286"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2893.2008.01011.x","article-title":"A class C CpG toll-like receptor 9 agonist successfully induces robust interferon-alpha production by plasmacytoid dendritic cells from patients chronically infected with hepatitis C","volume":"16","author":"Libri","year":"2009","journal-title":"J. Viral Hepat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2036.2011.04745.x","article-title":"Randomised clinical trial: Anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV","volume":"34","author":"Bergmann","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3851\/IMP2023","article-title":"Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7","volume":"17","author":"Boonstra","year":"2012","journal-title":"Antivir. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/hep.21773","article-title":"Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus","volume":"46","author":"McHutchison","year":"2007","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/hep.22547","article-title":"Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo","volume":"48","author":"Meuleman","year":"2008","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2012.02.018","article-title":"Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice","volume":"57","author":"Lacek","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/hep.27196","article-title":"Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents","volume":"60","author":"Vercauteren","year":"2014","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/gutjnl-2013-306155","article-title":"Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C","volume":"64","author":"Xiao","year":"2015","journal-title":"Gut"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/ATVBAHA.109.191320","article-title":"Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor","volume":"29","author":"Masson","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/infdis\/jit503","article-title":"Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: A randomized, double-blind, phase 1b study","volume":"209","author":"Sulkowski","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nbt.3179","article-title":"Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody","volume":"33","author":"Mailly","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nm.2581","article-title":"Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor","volume":"18","author":"Sainz","year":"2012","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jhep.2012.09.034","article-title":"Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period","volume":"58","author":"Marino","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jama.2012.8265","article-title":"Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: A randomized controlled trial","volume":"308","author":"Fried","year":"2012","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMc1307787","article-title":"HCV infection and miravirsen","volume":"369","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.antiviral.2014.08.015","article-title":"Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients","volume":"111","author":"Maan","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/hep.23787","article-title":"Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy","volume":"52","author":"Harrison","year":"2010","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/j.gastro.2010.08.055","article-title":"Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C","volume":"140","author":"Rao","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/hep.27960","article-title":"Alisporivir plus ribavirin, interferon-free or in combination with peg-interferon, for HCV genotype 2 or 3 infection","volume":"62","author":"Pawlotsky","year":"2015","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2012.02.024","article-title":"The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection","volume":"57","author":"Hopkins","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.antiviral.2011.01.003","article-title":"Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy","volume":"89","author":"Lawitz","year":"2011","journal-title":"Antivir. Res."},{"key":"ref_35","first-page":"860","article-title":"Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection","volume":"10","author":"Durantel","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jhep.2011.02.011","article-title":"Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism","volume":"55","author":"Goldwasser","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2893.2005.00718.x","article-title":"Effects of bezafibrate in patients with chronic hepatitis C virus infection: Combination with interferon and ribavirin","volume":"13","author":"Fujita","year":"2006","journal-title":"J. Viral Hepat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2893.2011.01524.x","article-title":"Thymosin alpha-1 with peginterferon alfa-2a\/ribavirin for chronic hepatitis C not responsive to IFN\/ribavirin: An adjuvant role?","volume":"19","author":"Ciancio","year":"2012","journal-title":"J. Viral Hepat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.gastro.2008.11.037","article-title":"Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin","volume":"136","author":"Rossignol","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/liv.12267","article-title":"Nitazoxanide plus pegylated interferon and ribavirin in the treatment of genotype 4 chronic hepatitis C, a randomized controlled trial","volume":"34","author":"Shehab","year":"2014","journal-title":"Liver Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"41003","DOI":"10.1074\/jbc.M302267200","article-title":"Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate","volume":"278","author":"Barth","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"10579","DOI":"10.1128\/JVI.00941-06","article-title":"Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction","volume":"80","author":"Barth","year":"2006","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1053\/j.gastro.2008.07.018","article-title":"Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion","volume":"135","author":"Haberstroh","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1128\/JVI.07222-11","article-title":"Hepatitis C Virus Attachment Mediated by Apolipoprotein E Binding to Cell Surface Heparan Sulfate","volume":"86","author":"Jiang","year":"2012","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e67982","DOI":"10.1371\/journal.pone.0067982","article-title":"Apolipoprotein E mediates attachment of clinical hepatitis C virus to hepatocytes by binding to cell surface heparan sulfate proteoglycan receptors","volume":"8","author":"Jiang","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1128\/JVI.03647-14","article-title":"Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans","volume":"89","author":"Xu","year":"2015","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6866","DOI":"10.1128\/JVI.03475-12","article-title":"Syndecan-1 Serves as the Major Receptor for Attachment of Hepatitis C Virus to the surface of hepatocytes","volume":"87","author":"Shi","year":"2013","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e95550","DOI":"10.1371\/journal.pone.0095550","article-title":"Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E","volume":"9","author":"Lefevre","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4","article-title":"Low density lipoprotein receptor as a candidate receptor for hepatitis C virus","volume":"57","author":"Monazahian","year":"1999","journal-title":"J. Med. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"12766","DOI":"10.1073\/pnas.96.22.12766","article-title":"Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor","volume":"96","author":"Agnello","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"10055","DOI":"10.1128\/JVI.74.21.10055-10062.2000","article-title":"Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor","volume":"74","author":"Wunschmann","year":"2000","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/jmv.10196","article-title":"Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption","volume":"68","author":"Germi","year":"2002","journal-title":"J. Med. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1128\/JVI.02017-13","article-title":"Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus","volume":"88","author":"Prentoe","year":"2014","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1093\/emboj\/cdf529","article-title":"The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus","volume":"21","author":"Scarselli","year":"2002","journal-title":"EMBO J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"41624","DOI":"10.1074\/jbc.M305289200","article-title":"Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor","volume":"278","author":"Bartosch","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1128\/JVI.79.9.5774-5785.2005","article-title":"Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes","volume":"79","author":"Barth","year":"2005","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1096\/fj.05-4728fje","article-title":"The interaction of natural hepatitis C virus with human scavenger receptor SR-BI\/Cla1 is mediated by ApoB-containing lipoproteins","volume":"20","author":"Maillard","year":"2006","journal-title":"Faseb J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e1000310","DOI":"10.1371\/journal.ppat.1000310","article-title":"Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains","volume":"5","author":"Dreux","year":"2009","journal-title":"PLoS Pathog."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"31242","DOI":"10.1074\/jbc.M112.365924","article-title":"Characterization of Hepatitis C Virus Particle Subpopulations Reveals Multiple Usage of the Scavenger Receptor BI for Entry Steps","volume":"287","author":"Granier","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrmicro3098","article-title":"The ins and outs of hepatitis C virus entry and assembly","volume":"11","author":"Lindenbach","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/infdis\/jis273","article-title":"A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses","volume":"205","author":"Krepstakies","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"13783","DOI":"10.1128\/JVI.01091-07","article-title":"Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture","volume":"81","author":"Chang","year":"2007","journal-title":"J. Virol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"12680","DOI":"10.1128\/JVI.01476-09","article-title":"Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles","volume":"83","author":"Jiang","year":"2009","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.25501","article-title":"Role of low-density lipoprotein receptor in the hepatitis C virus life cycle","volume":"55","author":"Albecka","year":"2012","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbrc.2015.04.104","article-title":"Anti-HCV effect of Lentinula edodes mycelia solid culture extracts and low-molecular-weight lignin","volume":"462","author":"Matsuhisa","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1021\/bm0701651","article-title":"Viral inhibition studies on sulfated lignin, a chemically modified biopolymer and a potential mimic of heparan sulfate","volume":"8","author":"Raghuraman","year":"2007","journal-title":"Biomacromolecules"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/j.1462-5822.2007.00972.x","article-title":"Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection","volume":"9","author":"Andreo","year":"2007","journal-title":"Cell. Microbiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.virol.2009.08.037","article-title":"Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor","volume":"394","author":"Owen","year":"2009","journal-title":"Virology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e26637","DOI":"10.1371\/journal.pone.0026637","article-title":"Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry","volume":"6","author":"Maillard","year":"2011","journal-title":"PLoS ONE"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1128\/JVI.00194-15","article-title":"The Serum Very-Low-Density Lipoprotein Serves as a Restriction Factor against Hepatitis C Virus Infection","volume":"89","author":"Tao","year":"2015","journal-title":"J. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.282.5390.938","article-title":"Binding of hepatitis C virus to CD81","volume":"282","author":"Pileri","year":"1998","journal-title":"Science"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e1003244","DOI":"10.1371\/journal.ppat.1003244","article-title":"Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies","volume":"9","author":"Sourisseau","year":"2013","journal-title":"PLoS Pathog."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.26733","article-title":"Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry","volume":"59","author":"Douam","year":"2014","journal-title":"Hepatology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"8865","DOI":"10.1038\/srep08865","article-title":"A Dual-reporter system for real-time monitoring and high-throughput CRISPR\/Cas9 library screening of the hepatitis C virus","volume":"5","author":"Ren","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Hopcraft, S.E., and Evans, M.J. (2015). Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins. Hepatology.","DOI":"10.1002\/hep.27815"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e60333","DOI":"10.1371\/journal.pone.0060333","article-title":"Discovery of cellular proteins required for the early steps of HCV infection using integrative genomics","volume":"8","author":"Park","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm.2341","article-title":"EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy","volume":"17","author":"Lupberger","year":"2011","journal-title":"Nat. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"10777","DOI":"10.1073\/pnas.1301764110","article-title":"Identification of transferrin receptor 1 as a hepatitis C virus entry factor","volume":"110","author":"Martin","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1128\/JVI.02705-14","article-title":"AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets","volume":"89","author":"Neveu","year":"2015","journal-title":"J. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/v6020875","article-title":"CD81-receptor associations\u2014Impact for hepatitis C virus entry and antiviral therapies","volume":"6","author":"Zona","year":"2014","journal-title":"Viruses"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0042-6822(03)00406-9","article-title":"Small molecule inhibition of hepatitis C virus E2 binding to CD81","volume":"314","author":"VanCompernolle","year":"2003","journal-title":"Virology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1074\/jbc.M411555200","article-title":"Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake","volume":"280","author":"Cai","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1128\/JVI.02460-05","article-title":"Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses","volume":"80","author":"Koutsoudakis","year":"2006","journal-title":"J. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/hep.21406","article-title":"Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system","volume":"44","author":"Lavie","year":"2006","journal-title":"Hepatology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/hep.21994","article-title":"Scavenger receptor BI is a key host factor for Hepatitis C virus infection required for an entry step closely linked to CD81","volume":"46","author":"Zeisel","year":"2007","journal-title":"Hepatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/hep.23445","article-title":"Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations","volume":"51","author":"Krieger","year":"2010","journal-title":"Hepatology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1053\/j.gastro.2010.05.073","article-title":"Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes","volume":"39","author":"Fofana","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jhep.2010.06.024","article-title":"Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors","volume":"54","author":"Syder","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1016\/j.bmcl.2011.09.019","article-title":"Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors","volume":"21","author":"Mittapalli","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1016\/j.bmcl.2012.06.038","article-title":"Discovery of ITX 4520: A highly potent orally bioavailable hepatitis C virus entry inhibitor","volume":"22","author":"Mittapalli","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.25685","article-title":"A human claudin-1-derived peptide inhibits hepatitis C virus entry","volume":"56","author":"Si","year":"2012","journal-title":"Hepatology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.26097","article-title":"The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination","volume":"57","author":"Zahid","year":"2013","journal-title":"Hepatology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e64221","DOI":"10.1371\/journal.pone.0064221","article-title":"A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission","volume":"8","author":"Fofana","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.chom.2013.02.006","article-title":"HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex","volume":"13","author":"Zona","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1124\/jpet.114.217653","article-title":"Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus","volume":"353","author":"Yamashita","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1021\/jm501759m","article-title":"Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents","volume":"58","author":"Kovackova","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"9012","DOI":"10.1038\/srep09012","article-title":"Interferon-alpha inducible protein 6 impairs EGFR activation by CD81 and inhibits hepatitis C virus infection","volume":"5","author":"Meyer","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1128\/JVI.00024-06","article-title":"Hepatitis C virus entry depends on clathrin-mediated endocytosis","volume":"80","author":"Blanchard","year":"2006","journal-title":"J. Virol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/j.gastro.2009.04.048","article-title":"Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry","volume":"137","author":"Matsumura","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1002\/hep.23587","article-title":"Multiple effects of silymarin on the hepatitis C virus lifecycle","volume":"51","author":"Wagoner","year":"2010","journal-title":"Hepatology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.antiviral.2013.08.008","article-title":"Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking","volume":"100","author":"Blaising","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_102","first-page":"1866","article-title":"Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking","volume":"15","author":"Blaising","year":"2013","journal-title":"Cell. Microbiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/hep.26273","article-title":"The antimalarial ferroquine is an inhibitor of hepatitis C virus","volume":"58","author":"Vausselin","year":"2013","journal-title":"Hepatology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1053\/j.gastro.2009.11.053","article-title":"Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase","volume":"138","author":"Ahnou","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00535-009-0132-9","article-title":"Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy","volume":"45","author":"Mizui","year":"2010","journal-title":"J. Gastroenterol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hep.21959","article-title":"Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies","volume":"47","author":"Timpe","year":"2008","journal-title":"Hepatology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1128\/JVI.01592-10","article-title":"Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission","volume":"85","author":"Brimacombe","year":"2011","journal-title":"J. Virol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1099\/vir.0.006700-0","article-title":"CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells","volume":"90","author":"Witteveldt","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"8282","DOI":"10.1128\/JVI.01102-13","article-title":"Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission","volume":"87","author":"Catanese","year":"2013","journal-title":"J. Virol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hep.24692","article-title":"A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo","volume":"55","author":"Meuleman","year":"2012","journal-title":"Hepatology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1128\/JVI.03676-14","article-title":"Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model","volume":"89","author":"Fukasawa","year":"2015","journal-title":"J. Virol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jhep.2010.02.002","article-title":"Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy","volume":"52","author":"Neumann","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jcv.2010.07.006","article-title":"Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient","volume":"49","author":"Payer","year":"2010","journal-title":"J. Clin. Virol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"411","DOI":"10.5812\/hepatmon.6135","article-title":"Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection","volume":"12","author":"Aghemo","year":"2012","journal-title":"Hepat. Mon."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jhep.2012.10.009","article-title":"Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period","volume":"58","author":"Barcena","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1128\/jvi.66.3.1476-1483.1992","article-title":"Internal ribosome entry site within hepatitis C virus RNA","volume":"66","author":"Iizuka","year":"1992","journal-title":"J. Virol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1128\/jvi.67.6.3338-3344.1993","article-title":"Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism","volume":"67","author":"Wang","year":"1993","journal-title":"J. Virol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1101\/gad.12.1.67","article-title":"A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs","volume":"12","author":"Pestova","year":"1998","journal-title":"Genes Dev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1017\/S1355838201001790","article-title":"Mechanism of ribosome recruitment by hepatitis C IRES RNA","volume":"7","author":"Kieft","year":"2001","journal-title":"RNA"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.virol.2009.08.012","article-title":"A cell-permeable peptide inhibits hepatitis C virus replication by sequestering IRES transacting factors","volume":"394","author":"Fontanes","year":"2009","journal-title":"Virology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.4161\/rna.21208","article-title":"Targeting ribosome assembly on the HCV RNA using a small RNA molecule","volume":"9","author":"Bhat","year":"2012","journal-title":"RNA Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2015.01.013","article-title":"A new role for PGA1 in inhibiting hepatitis C virus-IRES-mediated translation by targeting viral translation factors","volume":"117","author":"Tsukimoto","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.1113329","article-title":"Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA","volume":"309","author":"Jopling","year":"2005","journal-title":"Science"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1038\/emboj.2008.244","article-title":"microRNA-122 stimulates translation of hepatitis C virus RNA","volume":"27","author":"Henke","year":"2008","journal-title":"EMBO J."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nsmb822","article-title":"Identification of the versatile scaffold protein RACK1 on the eukaryotic ribosome by cryo-EM","volume":"11","author":"Sengupta","year":"2004","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1128\/MCB.01718-08","article-title":"Direct link between RACK1 function and localization at the ribosome in vivo","volume":"29","author":"Coyle","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.cell.2014.10.041","article-title":"RACK1 controls IRES-mediated translation of viruses","volume":"159","author":"Majzoub","year":"2014","journal-title":"Cell"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molcel.2005.05.014","article-title":"Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase","volume":"19","author":"Watashi","year":"2005","journal-title":"Mol. Cell"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"12884","DOI":"10.1073\/pnas.0704894104","article-title":"Cellular cofactors affecting hepatitis C virus infection and replication","volume":"104","author":"Randall","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/hep.21608","article-title":"Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology","volume":"45","author":"Ng","year":"2007","journal-title":"Hepatology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1074\/jbc.M703988200","article-title":"Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening","volume":"283","author":"Supekova","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1073\/pnas.0902693106","article-title":"Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication","volume":"106","author":"Berger","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.chom.2009.02.001","article-title":"A functional genomic screen identifies cellular cofactors of hepatitis C virus replication","volume":"5","author":"Tai","year":"2009","journal-title":"Cell Host Microbe"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.virol.2009.02.039","article-title":"Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication","volume":"387","author":"Vaillancourt","year":"2009","journal-title":"Virology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1093\/jac\/dkv077","article-title":"A novel small-molecule inhibitor of hepatitis C virus replication acts by suppressing signal transducer and activator of transcription 3","volume":"70","author":"Niu","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1128\/JVI.76.12.5974-5984.2002","article-title":"Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex","volume":"76","author":"Egger","year":"2002","journal-title":"J. Virol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"12529","DOI":"10.1128\/JVI.01798-10","article-title":"Amphipathic alpha-helix AH2 is a major determinant for the oligomerization of hepatitis C virus nonstructural protein 4B","volume":"84","author":"Gouttenoire","year":"2010","journal-title":"J. Virol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1128\/JVI.00502-11","article-title":"NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes","volume":"85","author":"Paul","year":"2011","journal-title":"J. Virol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e1003056","DOI":"10.1371\/journal.ppat.1003056","article-title":"Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication","volume":"8","author":"Merz","year":"2012","journal-title":"PLoS Pathog."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1099\/vir.0.022186-0","article-title":"Ultrastructural and biochemical analyses of hepatitis C virus-associated host cell membranes","volume":"91","author":"Ferraris","year":"2010","journal-title":"J. Gen. Virol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3390\/v3081342","article-title":"Impact of the autophagy machinery on hepatitis C virus infection","volume":"3","author":"Dreux","year":"2011","journal-title":"Viruses"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Wang, L., and James Ou, J.H. (2015). Hepatitis C virus and autophagy. Biol. Chem.","DOI":"10.1515\/hsz-2015-0172"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"18036","DOI":"10.1074\/jbc.M111.320085","article-title":"Replication of hepatitis C virus RNA on autophagosomal membranes","volume":"287","author":"Sir","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.chom.2014.10.008","article-title":"Hepatitis C virus RNA replication and assembly: Living on the fat of the land","volume":"16","author":"Paul","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1053\/j.gastro.2014.01.055","article-title":"Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation","volume":"146","author":"Madan","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1128\/JVI.06001-11","article-title":"Proline-serine-threonine phosphatase-interacting protein 2 (PSTPIP2), a host membrane-deforming protein, is critical for membranous web formation in hepatitis C virus replication","volume":"86","author":"Chao","year":"2012","journal-title":"J. Virol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature12427","article-title":"Completion of the entire hepatitis C virus life cycle in genetically humanized mice","volume":"501","author":"Dorner","year":"2013","journal-title":"Nature"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1074\/jbc.M809244200","article-title":"Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis\/trans isomerase activity of cyclophilins A and B","volume":"284","author":"Hanoulle","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e1000546","DOI":"10.1371\/journal.ppat.1000546","article-title":"Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics","volume":"5","author":"Kaul","year":"2009","journal-title":"PLoS Pathog."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.virol.2009.10.043","article-title":"Multiple cyclophilins involved in different cellular pathways mediate HCV replication","volume":"397","author":"Gaither","year":"2010","journal-title":"Virology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2014.07.008","article-title":"Cyclophilin inhibition as potential therapy for liver diseases","volume":"61","author":"Naoumov","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1128\/AAC.00693-12","article-title":"The Cyclophilin Inhibitor SCY-635 Disrupts HCV NS5A-Cyclophilin A Complexes","volume":"56","author":"Hopkins","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/AAC.00660-09","article-title":"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro","volume":"54","author":"Hopkins","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1517\/13543784.2012.658641","article-title":"Update on alisporivir in treatment of viral hepatitis C","volume":"21","author":"Flisiak","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.chom.2010.12.002","article-title":"Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment","volume":"9","author":"Reiss","year":"2011","journal-title":"Cell Host Microbe"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e1003359","DOI":"10.1371\/journal.ppat.1003359","article-title":"The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A","volume":"9","author":"Reiss","year":"2013","journal-title":"PLoS Pathog."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1096\/fj.09-131920","article-title":"Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening","volume":"23","author":"Trotard","year":"2009","journal-title":"Faseb J."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"10058","DOI":"10.1128\/JVI.02418-08","article-title":"Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication","volume":"83","author":"Borawski","year":"2009","journal-title":"J. Virol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1128\/AAC.00946-12","article-title":"Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors","volume":"56","author":"Lamarche","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1128\/AAC.00303-13","article-title":"Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo","volume":"57","author":"Spickler","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1016\/j.bmcl.2014.07.015","article-title":"2-Alkyloxazoles as potent and selective PI4KIIIbeta inhibitors demonstrating inhibition of HCV replication","volume":"24","author":"Keaney","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/v5051292","article-title":"Hepatitis C virus, cholesterol and lipoproteins\u2014Impact for the viral life cycle and pathogenesis of liver disease","volume":"5","author":"Felmlee","year":"2013","journal-title":"Viruses"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"15669","DOI":"10.1073\/pnas.202608199","article-title":"Genomic analysis of the host response to hepatitis C virus infection","volume":"99","author":"Su","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"15865","DOI":"10.1073\/pnas.2237238100","article-title":"Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation","volume":"100","author":"Ye","year":"2003","journal-title":"Proc Proc. Natl. Acad. Sci. USA"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1073\/pnas.0409834102","article-title":"Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids","volume":"102","author":"Kapadia","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/hep.21232","article-title":"Different anti-HCV profiles of statins and their potential for combination therapy with interferon","volume":"44","author":"Ikeda","year":"2006","journal-title":"Hepatology"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000213504","article-title":"An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads","volume":"52","author":"Sezaki","year":"2009","journal-title":"Intervirology"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jvh.12274","article-title":"The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: A meta-analysis","volume":"21","author":"Grammatikos","year":"2014","journal-title":"J. Viral Hepat."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e80304","DOI":"10.1371\/journal.pone.0080304","article-title":"Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism","volume":"8","author":"Ali","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1053\/j.gastro.2007.08.002","article-title":"Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes","volume":"133","author":"Shan","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.23339","article-title":"The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response","volume":"51","author":"Lehmann","year":"2010","journal-title":"Hepatology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/hep.23921","article-title":"Biliverdin inhibits hepatitis C virus nonstructural 3\/4A protease activity: Mechanism for the antiviral effects of heme oxygenase?","volume":"52","author":"Zhu","year":"2010","journal-title":"Hepatology"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e96533","DOI":"10.1371\/journal.pone.0096533","article-title":"Matrix conditions and KLF2-dependent induction of heme oxygenase-1 modulate inhibition of HCV replication by fluvastatin","volume":"9","author":"Wuestenberg","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.antiviral.2012.05.006","article-title":"SKI-1\/S1P inhibition: A promising surrogate to statins to block Hepatitis C virus replication","volume":"95","author":"Blanchet","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e1002468","DOI":"10.1371\/journal.ppat.1002468","article-title":"Human subtilase SKI-1\/S1P is a master regulator of the HCV Lifecycle and a potential host cell target for developing indirect-acting antiviral agents","volume":"8","author":"Olmstead","year":"2012","journal-title":"PLoS Pathog."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"32765","DOI":"10.1074\/jbc.M704418200","article-title":"Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B","volume":"282","author":"Watashi","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1038\/srep07242","article-title":"Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms","volume":"4","author":"Chen","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/hep.27913","article-title":"Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication via blockage of membranous web formation","volume":"62","author":"Kusuma","year":"2015","journal-title":"Hepatology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"6805","DOI":"10.1128\/JVI.00587-15","article-title":"Identification of Cholesterol 25-Hydroxylase as a Novel Host Restriction Factor and a Part of the Primary Innate Immune Responses against Hepatitis C Virus Infection","volume":"89","author":"Xiang","year":"2015","journal-title":"J. Virol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.immuni.2012.11.005","article-title":"Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol","volume":"38","author":"Liu","year":"2013","journal-title":"Immunity"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"8215","DOI":"10.1128\/JVI.02575-07","article-title":"Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells","volume":"82","author":"Chang","year":"2008","journal-title":"J Virol"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"12087","DOI":"10.1128\/JVI.05843-11","article-title":"HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle","volume":"85","author":"Narbus","year":"2011","journal-title":"J. Virol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1128\/JVI.06242-11","article-title":"Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122","volume":"86","author":"Kambara","year":"2012","journal-title":"J. Virol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"11919","DOI":"10.1128\/JVI.01066-12","article-title":"Reconstitution of the entire hepatitis C virus life cycle in non-hepatic cells","volume":"86","author":"Turek","year":"2012","journal-title":"J. Virol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"7918","DOI":"10.1128\/JVI.00567-12","article-title":"Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus","volume":"86","author":"Fukuhara","year":"2012","journal-title":"J. Virol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.chom.2008.05.013","article-title":"Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome","volume":"4","author":"Jopling","year":"2008","journal-title":"Cell Host Microbe"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.chom.2014.12.014","article-title":"miR-122 stimulates hepatitis C virus RNA synthesis by altering the balance of viral RNAs engaged in replication versus translation","volume":"17","author":"Masaki","year":"2015","journal-title":"Cell Host Microbe"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jhep.2014.10.004","article-title":"miR-122\u2014A key factor and therapeutic target in liver disease","volume":"62","author":"Bandiera","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/nar\/gkt852","article-title":"Miravirsen (SPC3649) can inhibit the biogenesis of miR-122","volume":"42","author":"Gebert","year":"2014","journal-title":"Nucl. Acids Res."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/hep.24160","article-title":"Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus","volume":"53","author":"Peng","year":"2011","journal-title":"Hepatology"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2011.07.026","article-title":"A functional genomic screen reveals novel host genes that mediate interferon-alpha\u2019s effects against hepatitis C virus","volume":"56","author":"Zhao","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1128\/JVI.00364-15","article-title":"EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I\/MDA5 Pathway","volume":"89","author":"Zhu","year":"2015","journal-title":"J. Virol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e0121608","DOI":"10.1371\/journal.pone.0121608","article-title":"Host APOBEC3G protein inhibits HCV replication through direct binding at NS3","volume":"10","author":"Zhu","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.bmcl.2015.04.016","article-title":"Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6","volume":"25","author":"Kozlov","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/jcb.24541","article-title":"Suppressive effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication","volume":"114","author":"Sato","year":"2013","journal-title":"J. Cell. Biochem."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"9599","DOI":"10.1073\/pnas.171311298","article-title":"Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B","volume":"98","author":"Gong","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.virol.2006.02.023","article-title":"Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes","volume":"349","author":"Basu","year":"2006","journal-title":"Virology"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1002\/hep.26496","article-title":"Signal transducer and activator of transcription 3 is a proviral host factor for hepatitis C virus","volume":"58","author":"McCartney","year":"2013","journal-title":"Hepatology"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1128\/JVI.76.14.6919-6928.2002","article-title":"Characterization of low- and very-low-density hepatitis C virus RNA-containing particles","volume":"76","author":"Andre","year":"2002","journal-title":"J. Virol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3390\/biology3040892","article-title":"Hepatitis C virus life cycle and lipid metabolism","volume":"3","author":"Popescu","year":"2014","journal-title":"Biology"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1128\/JVI.02053-07","article-title":"Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion","volume":"82","author":"Gastaminza","year":"2008","journal-title":"J. Virol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1083\/jcb.201311051","article-title":"Review: Biogenesis of the multifunctional lipid droplet: Lipids, proteins, and sites","volume":"204","author":"Pol","year":"2014","journal-title":"J. Cell Biol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/ncb1631","article-title":"The lipid droplet is an important organelle for hepatitis C virus production","volume":"9","author":"Miyanari","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1021\/jm4007033","article-title":"Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors","volume":"56","author":"DeVita","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/nm.2238","article-title":"Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1","volume":"16","author":"Herker","year":"2010","journal-title":"Nat. Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e1002829","DOI":"10.1371\/journal.ppat.1002829","article-title":"MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles","volume":"8","author":"Menzel","year":"2012","journal-title":"PLoS Pathog."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.00688-11","article-title":"Activation of the Ras\/Raf\/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway","volume":"86","author":"Zhang","year":"2012","journal-title":"J. Virol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.virol.2005.06.015","article-title":"Enhancement of internal ribosome entry site-mediated translation and replication of hepatitis C virus by PD98059","volume":"340","author":"Murata","year":"2005","journal-title":"Virology"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"e7498","DOI":"10.1371\/journal.pone.0007498","article-title":"Up-regulation of hepatitis C virus replication and production by inhibition of MEK\/ERK signaling","volume":"4","author":"Ndjomou","year":"2009","journal-title":"PLoS ONE"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s12250-012-3257-6","article-title":"Regulation of hepatitis C virus replication and gene expression by the MAPK-ERK pathway","volume":"27","author":"Pei","year":"2012","journal-title":"Virol. Sin."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"13025","DOI":"10.1128\/JVI.01785-12","article-title":"Cytosolic phospholipase A2 gamma is involved in hepatitis C virus replication and assembly","volume":"86","author":"Xu","year":"2012","journal-title":"J. Virol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"e1002845","DOI":"10.1371\/journal.ppat.1002845","article-title":"Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly","volume":"8","author":"Neveu","year":"2012","journal-title":"PLoS Pathog."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s10620-005-2788-1","article-title":"Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver","volume":"50","author":"Yamaguchi","year":"2005","journal-title":"Dig. Dis. Sci."},{"key":"ref_215","first-page":"683","article-title":"PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice","volume":"118","author":"Tanaka","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s10529-012-1034-0","article-title":"Resveratrol prevents hepatic steatosis induced by hepatitis C virus core protein","volume":"34","author":"Jiang","year":"2012","journal-title":"Biotechnol. Lett."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26634","article-title":"Hepatitis C virus induced up-regulation of microRNA-27: A novel mechanism for hepatic steatosis","volume":"59","author":"Singaravelu","year":"2014","journal-title":"Hepatology"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"e1000035","DOI":"10.1371\/journal.ppat.1000035","article-title":"Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly","volume":"4","author":"Appel","year":"2008","journal-title":"PLoS Pathog."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"7964","DOI":"10.1128\/JVI.00826-08","article-title":"Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles","volume":"82","author":"Masaki","year":"2008","journal-title":"J. Virol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"9915","DOI":"10.1074\/jbc.M112.434910","article-title":"Diacylglycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core","volume":"288","author":"Camus","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"e1000032","DOI":"10.1371\/journal.ppat.1000032","article-title":"Regulation of hepatitis C virion production via phosphorylation of the NS5A protein","volume":"4","author":"Tellinghuisen","year":"2008","journal-title":"PLoS Pathog."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.1128\/JVI.03170-13","article-title":"Involvement of hepatitis C virus NS5A hyperphosphorylation mediated by casein kinase I-alpha in infectious virus production","volume":"88","author":"Masaki","year":"2014","journal-title":"J. Virol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"e113938","DOI":"10.1371\/journal.pone.0113938","article-title":"Casein kinase II inhibitor enhances production of infectious genotype 1a hepatitis C virus (H77S)","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"10288","DOI":"10.1158\/0008-5472.CAN-10-1893","article-title":"CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy","volume":"70","author":"Drygin","year":"2010","journal-title":"Cancer Res."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1073\/pnas.0700760104","article-title":"Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins","volume":"104","author":"Huang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/ATVBAHA.111.241471","article-title":"Intracellular trafficking and secretion of VLDL","volume":"32","author":"Tiwari","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1053\/j.gastro.2011.06.010","article-title":"Mouse hepatic cells support assembly of infectious hepatitis C virus particles","volume":"141","author":"Long","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hep.23278","article-title":"Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles","volume":"51","author":"Benga","year":"2010","journal-title":"Hepatology"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"11532","DOI":"10.1128\/JVI.01021-10","article-title":"The C-terminal alpha-helix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virus","volume":"84","author":"Cun","year":"2010","journal-title":"J. Virol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"18904","DOI":"10.1074\/jbc.M113.538256","article-title":"The association of hepatitis C virus glycoproteins with apolipoproteins E and B early in assembly is conserved in lipoviral particles","volume":"289","author":"Boyer","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"12422","DOI":"10.1128\/JVI.01660-14","article-title":"Apolipoprotein E likely contributes to a maturation step of infectious hepatitis C virus particles and interacts with viral envelope glycoproteins","volume":"88","author":"Lee","year":"2014","journal-title":"J. Virol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"e1002466","DOI":"10.1371\/journal.ppat.1002466","article-title":"Molecular determinants and dynamics of hepatitis C virus secretion","volume":"8","author":"Coller","year":"2012","journal-title":"PLoS Pathog."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1042\/CS20120594","article-title":"Amiodarone inhibits the entry and assembly steps of hepatitis C virus life cycle","volume":"125","author":"Cheng","year":"2013","journal-title":"Clin. Sci."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/187221412799015290","article-title":"Emerging therapies for dyslipidemia: Known knowns and known unknowns of MTP inhibitors","volume":"6","author":"Raval","year":"2012","journal-title":"Recent Pat. Endocr. Metab. Immune Drug Discov."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/JVI.02068-13","article-title":"Hepatocyte nuclear factor 4alpha and downstream secreted phospholipase A2 GXIIB regulate production of infectious hepatitis C virus","volume":"88","author":"Li","year":"2014","journal-title":"J. Virol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/1743-422X-8-329","article-title":"Inhibition of cyclophilins alters lipid trafficking and blocks hepatitis C virus secretion","volume":"8","author":"Anderson","year":"2011","journal-title":"Virol. J."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.23766","article-title":"Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA","volume":"52","author":"Peng","year":"2010","journal-title":"Hepatology"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1016\/j.bmcl.2013.02.089","article-title":"Evaluation of anti-HCV activity and SAR study of (+)-lycoricidine through targeting of host heat-stress cognate 70 (Hsc70)","volume":"23","author":"Chen","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"e58675","DOI":"10.1371\/journal.pone.0058675","article-title":"N-substituted benzyl matrinic acid derivatives inhibit hepatitis C virus (HCV) replication through down-regulating host heat-stress cognate 70 (Hsc70) expression","volume":"8","author":"Du","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"561","DOI":"10.4155\/fmc.15.14","article-title":"Lycorine-derived phenanthridine downregulators of host Hsc70 as potential hepatitis C virus inhibitors","volume":"7","author":"Chen","year":"2015","journal-title":"Future Med. Chem."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/hep.22852","article-title":"The heat shock cognate protein 70 is associated with hepatitis C virus particles and modulates virus infectivity","volume":"49","author":"Parent","year":"2009","journal-title":"Hepatology"},{"key":"ref_242","first-page":"71","article-title":"Assembly of a functional HCV glycoprotein heterodimer","volume":"9","author":"Lavie","year":"2007","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1517\/14656566.2012.653341","article-title":"Treatment failure with new hepatitis C drugs","volume":"13","author":"Soriano","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","article-title":"In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","volume":"209","author":"Tong","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir","volume":"61","author":"Donaldson","year":"2015","journal-title":"Hepatology"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"e65273","DOI":"10.1371\/journal.pone.0065273","article-title":"Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures","volume":"8","author":"Bush","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"e1004128","DOI":"10.1371\/journal.ppat.1004128","article-title":"Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents","volume":"10","author":"Xiao","year":"2014","journal-title":"PLoS Pathog."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1126\/science.1178178","article-title":"Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection","volume":"327","author":"Lanford","year":"2010","journal-title":"Science"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1128\/AAC.01236-09","article-title":"Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors","volume":"54","author":"Puyang","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"e13687","DOI":"10.1371\/journal.pone.0013687","article-title":"DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A","volume":"5","author":"Coelmont","year":"2010","journal-title":"PLoS ONE"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1128\/AAC.00919-12","article-title":"Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir","volume":"56","author":"Bobardt","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coviro.2014.04.012","article-title":"Hepatitis C NS5A protein: Two drug targets within the same protein with different mechanisms of resistance","volume":"8","author":"Lim","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1038\/ncomms6408","article-title":"Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors","volume":"5","author":"Israelow","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_254","doi-asserted-by":"crossref","unstructured":"Colpitts, C.C., Zeisel, M.B., and Baumert, T.F. (2015). When one receptor closes, another opens: Claudins and the hepatitis C virus E1 glycoprotein. Hepatology.","DOI":"10.1002\/hep.27876"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/7\/11\/2898\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:51:20Z","timestamp":1760215880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/7\/11\/2898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,2]]},"references-count":254,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11]]}},"alternative-id":["v7112898"],"URL":"https:\/\/doi.org\/10.3390\/v7112898","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,2]]}}}